CLEAN - Clean Science and Technology Limited Share Price

In the Q4 earnings call for the financial year ended March 31, 2026, management of Clean Science and Technology Limited provided a cautiously optimistic outlook. They noted a resilient performance despite ongoing global challenges, including geopolitical uncertainties. The company reported a quarterly revenue increase of 8% sequentially to INR 193 crores, driven by higher customer offtake, while highlighting that full-year revenues saw a decline of 12% to approximately INR 800 crores due to the loss of a major FMCG customer and pricing pressures.

Management indicated that for FY27, the expectation is for gradual improvement, particularly in the hydroxyalkylated products (HALS) segment, which achieved record revenue in Q4 FY26, largely through increased export volumes, now approximately 50% of total HALS sales. They expect this upward trend to continue, with the possibility of enhancing production and expanding operational efficiency through debottlenecking efforts.

A significant forward-looking point highlighted was the anticipated capex of around INR 200 crores for Clean Fino-Chem, enabling better backward integration in key raw materials. The Performance Chemical 2 project is expected to be commercialized by September 2026. Additionally, a final dividend of INR 4 per equity share was declared, reflecting management's commitment to shareholder returns.

Overall, management remains cautious about the financial year ahead, citing global macroeconomic factors as challenges, yet indicates potential for volume and margin recovery driven by improvements in their product portfolio and market dynamics. The EBITDA margin for Q4 was recorded at 46%, with PAT at INR 77 crores.

1. Question: "Can you help us with the segmental numbers for the Performance, Pharma-Agro, FMCG, and others for the quarter and the full year?"
   Answer: "For the full year, the Performance segment contributed 72%, Pharma-Agro 19%, and FMCG accounted for 9% of our standalone revenues. I will provide the quarterly numbers later, but for a quick estimate, you can derive them by subtracting the nine-month figures from the full year."

2. Question: "What led to the sharp increase in HALS revenue, and how sustainable are these numbers?"
   Answer: "The increase in HALS revenue resulted from delayed customer evaluations and trials which finally bore fruit. We're now seeing significant export growth, shifting from an 80%-20% domestic-export ratio to 50% exports. It's sustainable as we continue debottlenecking and expanding our product capabilities."

3. Question: "How should we envision FY27 panning out for us, considering the traction in HALS?"
   Answer: "FY27 will be tricky due to global macro factors like crude oil supply and geopolitical tensions. Currently, we cannot provide precise projections. However, if price differentials normalize globally, we aim for positive growth."

4. Question: "Could you clarify your plans for expanding HALS capacity after reaching optimal utilization?"
   Answer: "Capacity increases require a long-term view. We're actively exploring debottlenecking and backward integration to accommodate increased demand, but any expansion will follow careful analysis and planning, given the complexities involved."

5. Question: "What is the forecasted capex budget for FY27?"
   Answer: "Our capex budget for FY27 is expected to range between INR 80 crores to INR 100 crores, reflecting our strategic investments as needed for growth initiatives."

6. Question: "Can you share any updates on the performance bonuses and what the exact amounts reversed were?"
   Answer: "We reversed performance bonuses amounting to roughly INR 11 crores this year. The full year bonus is significantly reduced as the Promoter Directors volunteered to forgo a portion to align with shareholder interests."